Medical school in Boston, MA
POPULARITY
Categories
219 episodes with Harvard Medical School
89 episodes with Harvard Medical School
93 episodes with Harvard Medical School
31 episodes with Harvard Medical School
55 episodes with Harvard Medical School
21 episodes with Harvard Medical School
18 episodes with Harvard Medical School
25 episodes with Harvard Medical School
14 episodes with Harvard Medical School
57 episodes with Harvard Medical School
31 episodes with Harvard Medical School
24 episodes with Harvard Medical School
21 episodes with Harvard Medical School
35 episodes with Harvard Medical School
29 episodes with Harvard Medical School
34 episodes with Harvard Medical School
20 episodes with Harvard Medical School
20 episodes with Harvard Medical School
22 episodes with Harvard Medical School
25 episodes with Harvard Medical School
13 episodes with Harvard Medical School
9 episodes with Harvard Medical School
18 episodes with Harvard Medical School
10 episodes with Harvard Medical School
10 episodes with Harvard Medical School
17 episodes with Harvard Medical School
11 episodes with Harvard Medical School
12 episodes with Harvard Medical School
9 episodes with Harvard Medical School
16 episodes with Harvard Medical School
17 episodes with Harvard Medical School
11 episodes with Harvard Medical School
34 episodes with Harvard Medical School
18 episodes with Harvard Medical School
14 episodes with Harvard Medical School
8 episodes with Harvard Medical School
13 episodes with Harvard Medical School
11 episodes with Harvard Medical School
17 episodes with Harvard Medical School
18 episodes with Harvard Medical School
26 episodes with Harvard Medical School
10 episodes with Harvard Medical School
8 episodes with Harvard Medical School
7 episodes with Harvard Medical School
7 episodes with Harvard Medical School
12 episodes with Harvard Medical School
6 episodes with Harvard Medical School
11 episodes with Harvard Medical School
9 episodes with Harvard Medical School
10 episodes with Harvard Medical School
9 episodes with Harvard Medical School
17 episodes with Harvard Medical School
10 episodes with Harvard Medical School
10 episodes with Harvard Medical School
In episode 62 of Going anti-Viral, Dr Rochelle Walensky joins host Dr Michael Saag on World AIDS Day 2025 to discuss her experience as the Director of the Centers for Disease Control and Prevention (CDC) during the COVID-19 pandemic and the current state of public health in the United States. Dr Walensky is a Professor of Medicine at Harvard Medical School and has published over 300 research articles that have motivated changes to US HIV testing and immigration policy and promoted expanded funding for HIV-related research, treatment, and the President's Emergency Plan for AIDS Relief (PEPFAR). Dr Walensky reflects on her experience during the early months of the COVID-19 pandemic in Massachusetts where she was the Chief of the Division of Infectious Diseases at Massachusetts General Hospital. Dr Saag and Dr Walensky then discuss her transition to the Director of the CDC and her management of the agency during the pandemic. Dr Walensky and Dr Saag emphasize the dedication of public health professionals and the need for continued support and understanding of the challenges they face. They discuss the risk of proposed budget cuts to the CDC and the impacts this will have on the agency as well as state and local public health departments. Finally, they discuss the future of public health and their shared optimism for public health over the long-term.0:00 – Introduction1:41 – Management of the early outbreak of COVID-19 in Massachusetts and reflections on the Conference on Retroviruses and Opportunistic Infections (CROI) in March of 202011:50 – Transition to lead the CDC and reflections on the difficult job of management of the CDC during a pandemic24:00 – Navigating COVID-19 variants and the challenge of public health recommendations for wearing masks and vaccination28:24 – Outlook on the future of public health and the CDC and the risks of proposed budget cuts on state and local public health agencies __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
Is exercise the ultimate catalyst for brain development, learning, and performance? The evidence is clear: exercise and brain performance are intrinsically linked. From resistance training to aerobic workouts, exercise physically transforms our brains, enhances performance and serves as our strongest defense against mood disorders, Alzheimer’s, ADHD, and addiction. This week on Krush Performance, we dive deep with Dr. John Ratey, renowned author and Associate Clinical Professor of Psychiatry at Harvard Medical School. We explore “A User’s Guide to the Brain” and delve into “Spark: The Revolutionary New Science of Exercise and the Brain.” Unlock your mental potential to conquer stress, sharpen your thinking, elevate your mood, boost your memory, and elevate your performance to new heights. Join us for this compelling conversation about the brain-body connection—a vital relationship in Creating More Coachable Players. Tune in and transform your approach to player development. The 20th season of Krush Performance is in full swing! Have a favorite guest or topic you'd like us to revisit? Or a burning issue you want us to investigate? Let us know at jeffkrushell.com. While you're there, subscribe to the Krush podcast and sign up for our weekly newsletter to stay on the cutting edge of human performance. Subscribe to the show on Apple Podcasts, Spotify, iHeartRadio, and TuneIn Radio! Don't forget to rate and review the show! Follow @JeffKrushell for weekly updates, show notes, and behind-the-scenes insight from Krush's CREATING COACHABLE PLAYERS PROGRAM. E-Mail Jeff with your questions and comments for the show and don't forget to visit KrushPerformance.com for live streaming, blogs, links, and so much more The post Episode 25-21: The User’s Guide to the Brain & Spark Dr. John Ratey appeared first on Radio Influence.
Send us a textMost people think memory loss is a downhill slide you can't stop. We don't. In this conversation with neurologist and neuroscientist Dr. Majid Fotuhi, we map out a twelve‑week blueprint that measurably improves memory, focus, and even grows hippocampal volume by targeting the real drivers of decline: poor sleep, chronic stress, insulin resistance, hearing loss, inactivity, and hidden medical issues.Dr. Majid Fotuhi is a pioneering neurologist, neuroscientist, and professor with more than thirty-five years of experience in brain health, memory, neuroplasticity, and the prevention of Alzheimer's disease. His work bridges research, clinical innovation, and public education.He earned his PhD in neuroscience from Johns Hopkins University, completed medical training at Harvard Medical School, and returned to Johns Hopkins for his neurology residency. He currently serves as an adjunct professor at Johns Hopkins University.An author and communicator, Dr. Fotuhi has written several books and is known for making complex science accessible. His excellence in teaching earned him the American Academy of Neurology's prestigious award. His research has appeared in peer-reviewed journals, been presented at major conferences, and cited widely by scientists worldwide.Dr. Fotuhi has created a twelve-week program that has helped thousands of patients with memory loss, brain fog, concussion, mild cognitive impairment, and early Alzheimer's disease. His expertise has been featured by CNN, NBC News, the Today Show, ABC News, The New York Times, The Washington Post, and The Times (London).We start by clarifying what mild cognitive impairment is, how it differs from dementia, and why so many cases are preventable. Dr. Fotuhi explains the “type 3 diabetes” model—how decades of sugar spikes and inflammation erode the blood‑brain barrier and starve neurons of a stable environment. Then we get practical. You'll hear how a personalized “brain portfolio” guides treatment: VO2 max testing to shape exercise, sleep studies and CPAP when needed, targeted brain training that matches deficits, and labs for vitamin D, B12, and omega‑3 status. The results? Early wins in two to three weeks, statistically significant gains at six and twelve, and habits that stick.We don't stop at diet and steps. Oral health impacts cognition by limiting whole foods and increasing inflammation; chewing itself engages neural circuits. Hearing loss quietly accelerates decline—hearing aids can move people from mild impairment back to normal. Add a simple, sustainable food approach—ditch ultra‑processed foods, eat vegetables, legumes, fruits, quality proteins, and healthy fats—and consider targeted supplementation with DHA/EPA omega‑3s and corrected D and B12 levels. Along the way, we address why amyloid hogged the spotlight, and point to powerful data: the Lancet's estimate that 45% of dementia cases are preventable and the American Heart Association's claim that 80% of strokes can be avoided.If you want a sharper brain by summer, this is your starting line. Subscribe, share this with someone you love, and leave a review telling us the one habit you'll change this week. Your future brain will thank you.Links:Majid Fotuhi, MD, PhD: https://drfotuhi.com/https://krieger.jhu.edu/mbi/directory/majid-fotuhi/https://neurogrow.com/about-us/dr-majid-fotuhi-md-phd/https://psychology.columbian.gwu.edu/majid-fotuhiTweet me @realdrhamrahIG @drhamrah
Enid Martinez, MD is a Senior Associate in Critical Care at Boston Children's Hospital, and an Assistant Professor of Anaesthesia at Harvard Medical School. She is the Director of the Pediatric Critical Care Nutrition Program in the Division of Critical Care Medicine and Principal Investigator for a clinical-translational research program on gastrointestinal function and nutrition in pediatric critical illness. Learning Objectives:By the end of this podcast, listeners should be able to:Recognize the impact of nutritional status on outcomes of critically-ill children.Describe the key aspects of the metabolic stress response in critical illness.Discuss a clinical approach to accurately estimating and prescribing nutrition in critically-ill children.Reflect on an expert's approach to managing aspects of nutrition in critically-ill children where there may not be high-quality evidence. Selected references:Mehta et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):706-742. doi: 10.1177/0148607117711387. Epub 2017 Jun 2. PMID: 28686844. Fivez et al. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med. 2016 Mar 24;374(12):1111-22. doi: 10.1056/NEJMoa1514762. Epub 2016 Mar 15. PMID: 26975590.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.
In today's episode, we had the pleasure of speaking with Jacob Sands, MD, and Shailee Shah, MD, about considerations for diagnosing and managing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC). Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the Oncology Medical Director of the International Patient Center at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In our exclusive interview, Drs Sands and Shah discussed LEMS symptom identification, the importance of paraneoplastic panels for assessing neurologic dysfunction in patients with SCLC, the need for specific autoantibody testing, and what guidelines currently note as best practices for the diagnosis of this disease.
German-born spiritual teacher and self-help author Eckhart Tolle once wrote, "Acknowledging the good that you already have in your life is the foundation for all abundance." I found this to be true in my life as well, and as it turns out, expressing gratitude isn't just a sound spiritual practice. It's essential to our emotional and physical well-being. According to a recent study performed at Harvard Medical School, "Gratitude is strongly and consistently associated with greater happiness. Gratitude helps people feel more positive emotions, relish good experiences, improve their health, deal with adversity, and build strong relationships." How can you reap the benefits? While there are many beneficial exercises that can help you cultivate an attitude of gratitude, such as journaling, morning or evening reflections, and performing acts of kindness, many people focus their thoughts outward (Ex: I'm grateful for my children, a roof over my head, my job, etc.).It's easy to lose sight of the good in ourselves. Instead, let's focus inward. Tune in as Anthony and I share what we're grateful for about each Enneagram type and why you should be too.
This week we go back in time to 2020 to delve into the topic of fellow wellness and review a work from the Boston Children's group on fellow fears and stressors when beginning their training. Are there patterns amongst the fellow concerns that can be identified and used to inform interventions to help allay these fears and reduce the stress? We speak with Dr. David Brown, Associate Professor of Pediatrics, Harvard Medical School and also Dr. Tony Pastor who was then the ACHD Fellow at Boston Children's Hospital/Brigham and Women's Hospital about their thoughts on fellow fears and stressors as well as fellow (and doctor) wellness. doi: 10.1007/s00246-019-02276-z.
Happy Thanksgiving, gentlemen!In this Manlihood Thanksgiving Special, Josh dives deep into gratitude—what it is, what it isn't, why it matters, and how building a thankful mindset can shape stronger, healthier, more resilient men. This episode includes science-backed benefits, real talk about entitlement and complaining, powerful quotes, personal reflections, and a guided gratitude meditation to help you reset your heart and mind.If you need encouragement today—or want a new perspective on gratitude—you're in the right place.00:00 — Welcome + Thanksgiving intro01:00 — Why Thanksgiving is Josh's favorite tradition01:40 — Gratitude as an intentional practice02:10 — What gratitude really is: posture, mindset, discipline02:45 — How gratitude rewires your brain (UC Davis study)03:00 — Dopamine, motivation, and the science behind gratitude03:20 — APA: Gratitude reduces anxiety & depression03:40 — Harvard Medical School on sleep, immune function, stress resilience04:10 — Gratitude isn't weak — it's mental strength training04:30 — The opposites of gratitude04:45 — Entitlement: “I deserve this”05:10 — Complaining: “This isn't enough”05:30 — Taking things for granted06:00 — Quotes on gratitude from Aesop, David Steindl-Rast, Marcus Aurelius, and 1 Thess 5:1806:45 — Who are you grateful to?07:20 — Directing your gratitude toward real people07:45 — Josh's family Thanksgiving tradition08:00 — What Josh is thankful for this year10:00 — Gratitude for the Manlihood community10:30 — The Thanksgiving Weekend Gratitude Challenge11:00 — Guided Gratitude Meditation12:00 — Identifying something you're grateful for13:00 — Identifying someone you're grateful for13:30 — Being grateful for growth in yourself14:00 — Final Thanksgiving message & encouragement15:00 — Closing thoughts: Gratitude is a way of livingConnect with other men who want to grow, lead, and live with purpose.
Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use. Kevin Hill, MD, MHS, of Harvard Medical School joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence about the therapeutic use of cannabis and cannabinoids in adults, potential harms, and evidence-based clinical guidance. Related Content: Therapeutic Use of Cannabis and Cannabinoids
In this episode of More Than A Pretty Face, Dr. Azi speaks with Dr. Tomi Wall about modern rosacea management, including pulsed-dye lasers, V-Beam, combination treatments, and intradermal Botox for flushing. She then sits down with Dr. Monica Boen to discuss the resurgence of CO₂ and Erbium resurfacing lasers, evolving technology, and the cautious excitement around regenerative treatments like exosomes and PDRN. Both dermatologists share practical skincare advice, treatment philosophy, and their go-to in-office approaches for natural, effective results. Timeline of what was discussed: 00:00 – Podcast intro & welcome 00:07 – Introducing Dr. Tomi Wall 00:55 – Why rosacea emotionally affects patients 01:40 – Types of rosacea explained 02:35 – Top at-home treatments (azelaic acid, ivermectin, sulfur) 03:40 – In-office vascular treatments with PDL 04:40 – How vascular lasers improve rosacea 05:25 – V-Beam for scarring 06:15 – Best timing to start scar laser treatment 07:15 – Treating bruising immediately after filler 08:10 – V-Beam settings for bruising 09:00 – Botox for flushing & neurovascular mechanisms 10:00 – Dilution, dosing, safety precautions 11:05 – Topicals for temporary redness & rebound effects 12:00 – Rapid-fire questions 13:25 – Close of interview 1 15:25 – Introducing Dr. Boen & her practice 15:55 – Why CO₂ & Erbium ablative lasers are returning 16:35 – What ablative lasers do & why patients accept downtime 17:25 – UltraPulse CO₂ & Erbium for deep resurfacing 18:10 – UltraClear: lighter resurfacing with minimal downtime 19:10 – Choosing mild vs aggressive resurfacing settings 19:55 – Combination treatments (Pico, PDL, Fraxel, Clear & Brilliant) 20:40 – PDRN ("salmon DNA"): buzz vs data 21:40 – Exosomes: potential & regulatory concerns 22:50 – Real complications seen from unregulated injectables 23:35 – Dr. Boen's personal favorite treatments 24:10 – Daily skincare must-haves (SPF, retinoids, antioxidants) 25:00 – LED masks: when they help and when they don't 25:55 – Final message: patient education matters 26:40 – Podcast closing & where to submit questions ______________________________________________________________ Follow Tomi Wall on Instagram: @dr.tomileewall Dr. Tomi Wall is a laser fellowship–trained, board-certified dermatologist based in Northern California. With advanced training from Harvard Medical School and extensive experience teaching residents at Stanford, she specializes in vascular and laser-based treatments for rosacea, scarring, and inflammatory skin conditions. Dr. Wall is known for her research-informed approach, dedication to patient-centered care, and expertise in combination therapy to achieve natural, evidence-based outcomes. Follow Monica Boen on Instagram: @drmonicaboen Dr. Monica Boen is a board-certified dermatologist practicing in San Diego with advanced specialization in aesthetic and procedural dermatology. Trained in ablative and regenerative laser surgery, she is recognized for bringing modern innovation to legacy resurfacing technologies such as CO₂ and Erbium lasers. Dr. Boen is known for her comprehensive treatment planning, commitment to clinical safety, and ability to blend multiple modalities for powerful yet natural skin rejuvenation results. ______________________________________________________________ Submit your questions for the podcast to Dr. Azi on Instagram @morethanaprettyfacepodcast, @skinbydrazi, on YouTube, and TikTok @skinbydrazi. Email morethanaprettyfacepodcast@gmail.com. Shop skincare at https://azimdskincare.com and learn more about the practice at https://www.lajollalaserderm.com/ The content of this podcast is for entertainment, educational, and informational purposes and does not constitute formal medical advice. © Azadeh Shirazi, MD FAAD.
In this episode, host Shikha Jain, MD, speaks with Amy Comander, MD, about incorporating lifestyle medicine into cancer care, exciting advancements highlighted at the 2025 San Antonio Breast Cancer Symposium and more. • Welcome to another exciting episode of Oncology Overdrive 1:02 • About Comander 1:16 • The interview 3:42 • How do you find time to do everything that you do? 4:06 • When you started on your path, did you see your journey taking you to breast cancer, lifestyle medicine and authorship? How did you get to where you are today? 4:34 • Jain and Comander on the shifting mindset toward holistic patient care. 6:36 • Jain and Comander on the importance of lifestyle interventions in cancer care. 7:50 • Jain and Comander discuss optimizing survivorship. 9:04 • Tell us more about your latest book, PAVING Your Path Through Breast Cancer and Beyond […] What are you most excited about sharing from this book? 9:50 • Do you feel like this is a book for physicians, patients, caregivers or everyone? 11:47 • Is there anything related to lifestyle medicine, or breast oncology in general, that you are looking forward to hearing about at this year's San Antonio Breast Cancer Symposium? 14:38 • What are your thoughts on ESMO's latest press release regarding mRNA COVID vaccines and improved response to immunotherapy? 17:29 • Jain and Comander on specific lifestyle interventions to improve quality and quantity of life, as well as "guilty pleasures". 20:23 • How do you train for all the marathons you run, and when do you find the time to train regularly? 21:43 • What are the things that you are looking forward to seeing in the breast cancer space over the next decade in cancer care? 25:24 • If someone could only listen to the last minute of this episode, what would you want listeners to take away? 27:37 • How to contact Comander 28:45 • Thanks for listening 29:42 Amy Comander, MD, DipABLM, FACLM, MSCP, is a breast oncologist and medical director of the Mass General Brigham Cancer Institute in Waltham, director of the lifestyle medicine program at the Mass General Brigham Cancer Institute, and an instructor in medicine at Harvard Medical School. You can get a copy of her new book, PAVING Your Path Through Breast Cancer, here. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Comander can be reached on Instagram @dramycomander, LinkedIn, or via email acomander@mgh.harvard.edu. References • Grippin AJ, et al. Nature. 2025;doi:10.1038/s41586-025-09655-y. • PAVING the Path to Wellness. https://www.massgeneral.org/cancer-center/patient-and-family-resources/supportive-care/paving. Published 2021. Accessed November 11, 2026 Disclosures: Jain and Comander report no relevant financial disclosures.
Our guest this time is Stephen Duclos, and his interest in aging is partly because he has been doing social change work for decades and sees aging as just one more civil rights horizon. He's also interested in aging because he's a sex therapist, and he sees all sex as queer sex when it comes to aging adults. Stephen has been working as a therapist and counselor since 1972. He currently holds licenses and national certifications in Sex Therapy (as a CST), Couples and Family Therapy (LMFT), Mental Health Counseling (LMHC), and Rehabilitation Counseling (CRC). Stephen is an Approved Supervisor with the American Association for Marriage and Family Therapists (AAMFT), and AASECT (the American Association of Sex Educators, Counselors, and Therapists). He is also a member of the American Family Therapy Academy. In 2012, he received the Patricia Schiller award from AASECT for his work on Fathers, Adolescent Daughters, and Sexuality. And in 2022, he was featured in a cover story in the NY Times Magazine about sex over 70. Jane first met Stephen at an AASECT conference and was immediately struck by his candor, and they have been teaching social workers and students of sex therapy ever since. He is always up for a new challenge and is one of the most thoughtful clinicians she knows. He has been a teacher and supervisor of therapists as an adjunct faculty member of UMass/Boston and is a principal faculty member in the Sex Therapy Training program at South Shore Sexual Health Center. He has also taught at Boston Medical Center and Harvard Medical School. He is vitally interested in intimacy, aging, fathers and daughters, and long-term sexual relationships. Stephen has also been involved in civil rights work for more than 50 years. From registering voters for the Boston Election Commission in 1967, to helping establish the second Independent Living Center in the US for people with disabilities in the 1970s, to establishing biracial councils in the Boston Public Schools during desegregation through the late 1980s, to supporting liberation for the queer community, civil rights has been part of his ongoing, lifelong community work. His interest in aging comes in large part from his commitment to being a therapist, seeing older clients, and threading the aging process in the tapestry of his own life. He is fierce, tender, brilliant, and a great teacher and learner. He wanted to expand his teaching practice by working with a sex educator, and Jane was so pleased that he invited her in because she loves teaching with him, always learning something new, as we did in this conversation. Listeners, if you'd like to learn more about Stephen and his work, you can find more information here. If you want to catch up on other shows, just visit our website and please subscribe! We love our listeners and welcome your feedback, so if you love Our Better Half, please give us a 5-star rating and follow us on Facebook and Instagram. It really helps support our show! As always, thanks for listening!
Overview This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI)—including Lyme disease and other tick-borne infections—to the global Alzheimer's and neuroimmunology research community. Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight leading scientists connecting infection, immune dysfunction, and cognitive decline. This episode features Dr. Sean Miller, a neuroscientist and co-investigator in the Logan Lab with a primary appointment at Yale School of Medicine, who is developing ways to non-invasively detect Alzheimer's-like pathology through the eye. Guest Sean Miller, PhD Co-Investigator, Logan Lab / Yale School of Medicine Dr. Sean Miller completed pre-doctoral work at Harvard Medical School, earned his PhD from Johns Hopkins University, and completed post-doctoral training at Stanford University. His research focuses on neurodegeneration, neuroglia, and early diagnostic strategies for Alzheimer's and related diseases. At the AlzPI & PCOM Symposium, Dr. Miller presented evidence showing that SARS-CoV-2 (COVID-19) infection can accelerate Alzheimer's-like pathology and that these changes can be detected non-invasively through retinal imaging. His findings suggest that amyloid-beta, a protein long associated with Alzheimer's disease, may also serve as part of the brain's antimicrobial defense system—trapping pathogens like a mesh or biofilm, but leading to damaging plaque buildup when overproduced. Key Discussion Points Dr. Miller describes how the COVID-19 virus can act as an infectious trigger for neuroinflammation and amyloid buildup, how the eye provides a unique window into the brain, and why early detection is essential to preventing neuron death. He shares how his lab's AI-enhanced retinal imaging research at Yale Eye Center is identifying amyloid and tau deposits in patients with long COVID-related brain fog—opening the possibility of routine eye exams doubling as early Alzheimer's screening tools. He explains potential therapeutic strategies, such as limiting amyloid production during infection flare-ups and enhancing clearance mechanisms afterward to reduce chronic plaque formation. The conversation also explores his scientific journey—from designing Alzheimer's drugs at Harvard and Johns Hopkins to realizing the need for early disease detection during his postdoc at Stanford—and how the pandemic inspired his focus on infection-induced neurodegeneration. “We believe neurons are exposed to pathogens in the central nervous system and respond by secreting amyloid-beta to trap them. Excessive plaque buildup from repeated or severe infections may be what drives long-term neurodegeneration.” — Dr. Sean Miller Why It Matters Dr. Miller's research connects infectious disease, ophthalmology, and neurology, providing a revolutionary new method to screen for early Alzheimer's-like changes non-invasively through the human eye. His work suggests that infections like COVID-19 may trigger the same protective—but damaging—immune responses implicated in chronic conditions such as Alzheimer's disease and infection-associated cognitive decline. About the Event The interview took place at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, held on October 3, 2025, at Ohio University in Dublin, Ohio. The event brought together more than 20 global researchers exploring how microbes, the microbiome, and the immune response contribute to Alzheimer's, dementia, PANS/PANDAS, and infection-associated chronic illnesses (IACI). Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to share the voices of researchers advancing the field of infection-associated chronic illness. This episode is part of a multi-part Tick Boot Camp series highlighting how pathobiome and microbiome science are transforming the understanding of Lyme disease, infection, and neurodegeneration. Learn More Learn more about the Alzheimer's Pathobiome Initiative (AlzPI) Listen to Tick Boot Camp Podcast episodes, including Episode 406: Pathobiome – An Interview with Nikki Schultek and Episode 101: The Young Gun – An Interview with Alex (Ali) Moresco discussed in this interview.
Today, we'll talk with one of the true giants of stroke neurology - Dr. Louis Caplan, Professor of Neurology at Harvard Medical School and Senior Neurologist at Beth Israel Deaconess Medical Center. For decades, Dr. Caplan has shaped how we think about stroke. He's authored an enormous body of work -- landmark papers, books, and clinical descriptions that have changed how neurologists around the world recognize and classify strokes. But today, rather than revisiting the past, we'll ask how he sees the future - of stroke, clinical reasoning in an era of AI, and of medicine itself. Dr. Caplan was interviewed by Dr. Sarah Nelson, neurointensivist and Assistant Professor of Neurology at Tufts Medical Center. Series 7, Episode 2 Disclosures: None
Obesity is a chronic disease. So why are we still not treating it as such?Enter Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School and Massachusetts General Hospital.Dr. Stanford is a global voice on obesity - redefining it as a chronic disease, not a personal failure.In taking us through the science behind it, Dr. Stanford guides us to the heart of several patient stories, highlighting the need for treating patients with dignity, improving access to care, and eliminating biases in global healthcare.——We spoke about genetic, environmental, and systemic factors that contribute to obesity, the efficacy of treatments like GLP-1 receptor agonists, real-life examples, the emotional and practical aspects of this chronic disease, and the need to involve healthcare professionals, government, and the community to tackle the global obesity epidemic.Follow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4
In this episode of The Unfolding: Presented by The Loveland Foundation Podcast, host Rachel Keener talks with Dr. Charmain Jackman—CEO and founder of Innopsych and author of The Black Therapist Guide to Private Practice and Entrepreneurship. Together, they explore the ongoing need to make mental health care accessible, especially for Black women and girls.Dr. Jackman shares her path from Barbados to psychology, and how the struggle to find therapists of color inspired her to build Innopsych. She reflects on the platform's growth through the pandemic and racial justice movements, and the gaps she continues to see in support for clinicians—particularly around business training, sustainability, and burnout.They discuss what it means for healers to not just survive but truly thrive, and Dr. Jackman speaks openly about her own experiences with stress, boundaries, and rest. Dr. Jackman also shares the everyday practices that keep her grounded—family traditions, bold and expressive clothing, mindfulness rituals—and how joy can function as resistance, restoration, and a reminder of possibility.More about Dr. Charmain:Dr. Charmain Jackman is an award-winning psychologist, TEDx speaker, and entrepreneur with over two decades in mental health. She founded InnoPsych, connecting more than 10,000 people to therapists of color and expanding access to culturally responsive care.Her book, The Black Therapist's Guide to Private Practice and Entrepreneurship, supports BIPOC clinicians in building sustainable, profitable practices. A champion of mental health equity and workplace wellbeing, she has been recognized with honors such as the 2025 Boston Business Journal Innovators in Healthcare award and featured in outlets including Oprah Daily, Essence, NPR, the New York Times, and the Boston Globe.Dr. Jackman serves on the Massachusetts 988 Commission, holds a doctorate from the University of Southern Mississippi, and completed pediatric forensic psychology training at Harvard Medical School. She is also a wife and mom to two creative humans, grounding her in joy and compassion.–The Unfolding: Presented by The Loveland Foundation podcast is an additional resource not only to the public but also to our therapy fund cohort members. The Loveland Foundation therapy fund and resources are only made possible through support from our community. At The Loveland Foundation, we are committed to showing up for communities of color in unique and powerful ways, with a particular focus on Black women and girls. Our resources and initiatives are collaborative and they prioritize opportunity, access, validation, and healing. Since our founding, the Therapy Fund has provided financial support for therapy to over 13,000 Black women, girls, and non-binary individuals across the country.Links:Join The Abundance Collective: https://thelovelandfoundation.org/abundanceSupport the show: https://give.thelovelandfoundation.org/give/436656/#!/donation/checkoutFollow Dr. Charmain on Instagram: https://www.instagram.com/askdrcharmain/Follow The Loveland Foundation on Instagram: https://www.instagram.com/thelovelandfoundation/Visit the Loveland Foundation's website: https://thelovelandfoundation.org/Support the show
AI may be able to help in the fight against cancer. Kun-Hsing Yu, associate professor in the department of biomedical informatics at Harvard Medical School, looks into how it can help. Kun-Hsing “Kun” Yu, M.D., Ph.D., is an Associate Professor in the Department of Biomedical Informatics at Harvard Medical School. He pioneered the first fully […]
Altersforscherin Heike A. Bischoff-Ferrari und Musiker Lukas Hobi teilen sich bei Michèle Schönbächler die Bühne. Heike A. Bischoff-Ferrari, Ärztin und Forscherin für gesunde Langlebigkeit Seit Juli 2025 leitet Prof. Dr. Dr. Heike A. Bischoff-Ferrari den Schweizer Campus für gesunde Langlebigkeit an der Universität Basel und forscht mit ihren Kolleginnen und Kollegen über die Ausweitung der gesunden Lebensjahre. Sie wuchs in Ehingen im deutschen Bundesland Baden-Württemberg mit zwei Geschwistern auf. In ihren Jugendjahren wollte sie Künstlerin werden. In der Schüler-Lehrerband versuchte sie sich als Backgroundsängerin. «Nicht ganz so erfolgre.ich», wie sie mit einem Schmunzeln erwähnt. Umso erfolgreicher zeigt sie sich in ihre berufliche Karriere. Nach der Promotion und Assistenzarztzeit an der Universität Basel in den Fächern Geriatrie, Rheumatologie und Orthopädie arbeitete sie mehrere Jahre in Boston und war Fakultätsmitglied der Harvard Medical School. In dieser Zeit lernte sie ihren späteren Mann kennen. Nach ihrer Rückkehr in die Schweiz gründete sie in Zürich das Forschungszentrum «Alter und Mobilität» und baute den ersten Lehrstuhl für Altersmedizin und Altersforschung an der Universität Zürich auf, bevor sie im Sommer 2025 an die Universität nach Basel wechselte. Heike A. Bischoff-Ferrari ist fasziniert von der Weihnachtszeit und der Forschung zur gesunden Langlebigkeit, weil sie eine enorme Innovationskraft birgt. Sie leitet das Globale Konsortium zur Verlängerung der gesunden Lebenserwartung mit 12 Universitäten und ist Vernetzerin. ________________________________________ Lukas Hobi, Musiker «Ich hatte nie Ziele, aber ganz viele Träume», sagt Lukas Hobi. Und viele seiner Träume sind wahr geworden – nicht zuletzt, weil er überzeugt ist, Schmied seines eigenen Glücks zu sein. So stand er bereits auf zahlreichen Bühnen als Musical- und Theaterschauspieler. Mit der A-Capella-Comedy-Band Bliss tourt er durch die Schweiz und prägt die Gruppe als künstlerischer Leiter, Arrangeur und Mitproduzent weit über seine Stimme hinaus. Lukas Hobi ist zudem als Regisseur, Produzent und Komponist tätig. Sein Lied «Made in Switzerland» wurde am Eurovision Song Contest vor einem Millionenpublikum präsentiert. Beim Musikspektakel im Mai 2025 stand Lukas Hobi sogar als Backgroundsänger im St. Jakobpark in Basel auf der Bühne – und erzählt in der Sendung, warum die Technik dabei fast zur Hauptrolle wurde. Dabei war sein Weg alles andere als geradlinig: Nach seiner Ausbildung zum Lehrer unterrichtete er einige Wochen an einer Schule, bevor er sich für eine künstlerische Ausbildung zum Musicaldarsteller entschied. 2018 nutzte er eine mehrwöchige Auszeit, um sich in New York in Schauspiel, Tanz und Gesang weiterzubilden. Mit Bliss gewann Lukas Hobi dreimal den Swiss Comedy Award sowie den Prix Walo als Publikumslieblinge. Für seine Rolle als «Fritz Äberli» in der Produktion «Dällebach Kari» (Thunerseespiele, 2023) wurde er zudem als bester Nebendarsteller für den Deutschen Musicalpreis nominiert. Privat liebt Lukas Spieleabende mit seiner Familie – und hat gelernt, wie bereichernd es sein kann, auch mal allein zu reisen. ____________________ Moderation: Michèle Schönbächler ____________________ Das ist «Persönlich»: Jede Woche reden Menschen über ihr Leben, sprechen über ihre Wünsche, Interesse, Ansichten und Meinungen. «Persönlich» ist kein heisser Stuhl und auch keine Informationssendung, sondern ein Gespräch zur Person und über ihr Leben. Die Gäste werden eingeladen, da sie aufgrund ihrer Lebenserfahrungen etwas zu sagen haben, das über den Tag hinaus Gültigkeit hat.
On 28 September 2024, a conversation between Dr. Vivek Murthy, MD, US Surgeon General, and Sadhguru where they will explore "Loneliness: In is the Only Way Out". Hosted at the Joseph B. Martin Conference Room, Harvard Medical School, Boston, the session will be moderated by Bala Subramaniam, MD, MPH, Director of Sadhguru Center for a Conscious Planet. Set the context for a joyful, exuberant day with a short, powerful message from Sadhguru. Explore a range of subjects with Sadhguru, discover how every aspect of life can be a stepping stone, and learn to make the most of the potential that a human being embodies. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices
This week we review the topic of mitral annular disjunction ("MAD") and the possible association with ventricular arrhythmia or sudden death in the connective tissue disease patient. Is there a 'cut off' distance above which patients deserve more significant arrhythmia surveillance? What is the best way to measure the MAD distance? Can patients with low MAD distances have lower degrees or even no arrhythmic surveillance? How often should this distance be measured on CMR and can an echo measurement provide similar data? Dr. Daniel Castellanos, the first author of this work and Assistant Professor of Pediatrics at Harvard Medical School shares his deep insights this week.DOI: 10.1016/j.jocmr.2025.101954
On 28 September 2024, a conversation between Dr. Vivek Murthy, MD, US Surgeon General, and Sadhguru where they will explore "Loneliness: In is the Only Way Out". Hosted at the Joseph B. Martin Conference Room, Harvard Medical School, Boston, the session will be moderated by Bala Subramaniam, MD, MPH, Director of Sadhguru Center for a Conscious Planet. Set the context for a joyful, exuberant day with a short, powerful message from Sadhguru. Explore a range of subjects with Sadhguru, discover how every aspect of life can be a stepping stone, and learn to make the most of the potential that a human being embodies. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of the Dementia Researcher - Xxplored Women's Brain Health podcast, host Dr Laura Stankeviciute speaks with Professor Claudia Barth from Charite University and Dr Gillian Coughlan from Harvard Medical School to examine the midlife transition, menopause and its significance for women's brain health. Together they outline what the menopause truly involves across the early, late, and post stages, and explain how hormonal change affects brain structure, energy use, mood, and cognition. They also explore why this period may coincide with greater vulnerability to later Alzheimer's disease and discuss the role of early or surgical menopause, symptom severity, and gaps in existing research cohorts. The episode highlights the need for richer reproductive data, real time biomarker studies, and closer collaboration with digital health tools to better capture women's lived experiences. It reflects a growing wave of research and public interest aimed at improving understanding, support, and evidence based care during this important life stage. -- Takeaways ● Menopause is a long transition shaped by fluctuating hormones. ● Cognitive and mood symptoms reflect changes in brain networks. ● Earlier menopause is linked with increased later Alzheimer's risk. ● Major research cohorts lack detailed reproductive data. ● New real time studies are beginning to track symptoms and biomarkers. ● Digital tools will be key for future research. ● Better global representation is needed across studies. ● Momentum is building to close long standing gaps in women's health. -- Find bios on all our speakers, a full transcript of the show and more on our website at https://www.dementiaresearcher.nihr.ac.uk - Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher -- Chapters 00:00 Introduction to Menopause and Research Focus 07:25 Understanding Menopause: Definitions and Stages 16:27 Menopause and Alzheimer's Disease: A Critical Connection 22:43 Understanding Menopause and Brain Health 25:21 Historical Blind Spots in Alzheimer's Research 26:38 The Importance of Reproductive Variables 31:46 Biomarkers and Methodologies in Women's Health Research 35:28 Industry Collaboration in Research 39:00 Personal Reflections on Women's Brain Health
Many diets claim to be good for you. But the Mediterranean diet rises to the top with its research-proven benefits: it's been shown to increase life expectancy; decrease risk for dementia; improve mental health and cognitive function; and lower the risk of heart disease for nearly every demographic. What is it that makes the diet so great? In this episode, host Samantha Laine Perfas discuss the Mediterranean diet with nutritional psychiatrist Uma Naidoo and Mediterranean diet expert Miguel Ángel Martínez-González about how people can make nutritional changes that work for them day to day.
Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas" Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC, Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis, Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences
Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this compilation episode, Dr. Gabrielle Lyon is joined by the top experts in Testosterone and men's health treatments. You'll learn:Why aging alone doesn't drop T levels and why acquisition of conditions like obesity is the real culprit.Why the standard "low T" cutoff is misleading and why you must check your Free Testosterone.How erectile dysfunction is a sensitive marker of overall health and heart risk.The efficacy of Cialis/Viagra for both erections and cardiac protection, and the risks of unchecked influencer advice on steroids.The direct link between muscle mass, exercise, and sexual function—and why the penis is the "first to go" when overall health declines.Chapter Markers:0:00 - Testosterone is a Brain Hormone0:40 - Debunking the Myth: Male Menopause (Andropause) Doesn't Exist1:33 - The Dangers of Unchecked Influencer Advice on Testosterone3:07 - Defining Testosterone Deficiency: Symptoms vs. Signs5:10 - The Arbitrary Number: Why Guidelines Disagree on Low T8:29 - Free Testosterone: The Most Reliable Indicator of Male Health15:28 - TRT vs. Steroids: Defining the Line and Risks18:59 - The Real Risks of TRT: Infertility and Hematocrit22:36 - The Shocking Backstory: Challenging the Prostate Cancer Myth26:40 - Erectile Dysfunction (ED) and Lifestyle Modification29:21 - Shockwave Therapy for ED: The Science and the Cash Business33:53 - Penile Tissue Atrophy and Venous Leak37:25 - The Role of Muscle Mass, Sarcopenia, and Sexual Function39:41 - The Single Best Marker for Male Health: Erectile Function42:02 - The Science of Cialis and Viagra (PDE5 Inhibitors)45:49 - The Viagra Story: From Heart Drug to ED Cure50:50 - Tadalafil (Cialis) as a Triple-Threat Drug (Cardiac, Urinary, Sexual)53:57 - The Role of Testosterone in Female Sexual Function55:20 - Hypogonadism: Diagnosis, Treatment, and Fertility RiskAbout the guests: Dr. Abraham Morgentaler is an Associate Clinical Professor of Urology at Harvard Medical School and founder of Men's Health Boston. He is an internationally recognized expert in men's health, particularly known for his pioneering work in testosterone therapy. Dr. Morgentaler is credited with reversing the long-held belief that testosterone therapy causes prostate cancer and is the author of several books on men's health. YouTubeLinkedInT4L EducationX/Twitter Dr. Tobias Kohler is the co-founder of the Erectile Restoration Outcomes Study (EROS) penile implant registry. In addition to his clinical and research activities, Dr. Kohler is active in education, providing mentorship to residents and fellows.Mayo Clinic ResearchGateLinkedIn
This week, Thomas sits down with Dr. Richard Schwartz, the founder of Internal Family Systems, for an in-depth discussion on the power of healing in groups, intergenerational and ancestral trauma healing, and the relationship between therapy and spirituality—all topics that are featured in their forthcoming book; Releasing Our Burdens: A Guide to Healing Individual, Ancestral, and Collective Trauma.Thomas and Dr. Schwartz dive deep into the phenomena of ancestral and collective "legacy burdens", which are traumas from our shared past that unconsciously drive our current behavior and societal conflicts. They share therapeutic and spiritual strategies for addressing these inherited wounds, and discuss the urgent need for what Thomas calls a “collective healing architecture” to mend social fragmentation and revitalize our democratic systems.They also share insights on the importance of our interconnection with the natural world and the need for safe spaces to access “Self Energy,” where the profound impacts of individual parts work can amplify collective healing.✨ Watch the video version of this episode on YouTube:
I sit down with Dr. David Rosmarin, an associate professor at Harvard Medical School and a pioneer bridging the worlds of spirituality and clinical psychology. We explore a powerful, yet often ignored, truth in mental health: that for many, emotional distress is a crisis of meaning and spirit. David shares the fascinating research from his work at McLean Hospital, and we tackle the tough questions—are we over-medicalizing normal human anxiety? Could connecting with our spiritual nature be a more effective path to healing? This is a crucial conversation about bringing the soul back into mental health care.00:00 Intro02:42 The Genesis of Spirituality05:12 How Do You Define Spirituality?10:32 The Chasm Between Patient Needs and Clinical Training12:08 Humanizing Care: From Medication to Meaning18:21 A Case Study: Crisis of Meaning20:37 The Four Steps to Face Anxiety28:41 Anxiety as an Existential Opportunity31:01 Spiritual Mentorship: Crisis and Healing Are One34:40 Are We Over-Pathologizing Normal Anxiety?37:17 The Benzodiazepine Crisis and Over-Medication41:21 How to Find Dr. Rosmarin's Work42:53 Conclusion Learn more about Dr. David Rosmarin:· dhrosmarin.com· spirit.mclean.harvard.eduIn The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR - IG- https://tinyurl.com/ysvafdwc- FB - https://tinyurl.com/yc3z48v9- YT - https://tinyurl.com/ywdsc9vt- Web - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all means on Life, Death & the Space Between.**Brought to you by:Dr. Amy Robbins | Host, Executive ProducerPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.
Why is dating so hard in midlife? Are we all sending mixed signals? Abe Morgentaler, MD & Marianne Brandon, PhD are the hosts of the Sex Doctors Podcast, where they deep dive into the science & psychology of sexual health & relationships. Dr. Morgentaler is a Harvard trained MD who opened the first comprehensive men's health center in the US, is the leading authority in testosterone therapy, author of four books & currently the Blavatnik Faculty Fellow in Health & Longevity at Harvard Medical School. Dr. Brandon is a clinical psychologist, author & futurist whose professional writing includes aging & sex, the challenges of monogamy & female low libido. In this episode, you'll hear both personal & professional perspectives about the dating pool & approaches including app culture, dick pics, gender equality, hormones, “the ick” & desire-killing control. If you like this episode, you'll also like episode 180: IS YOUR ATTACHMENT STYLE RUINING YOUR RELATIONSHIP? Guests:Theirshttps://www.facebook.com/thesexdoctorshttps://www.youtube.com/@thesexdoctorspodhttps://www.instagram.com/thesexdoctors/Hershttps://www.psychologytoday.com/us/blog/the-future-intimacyhttps://a.co/d/8smce3Chttps://www.linkedin.com/in/mariannebrandon-59224513/https://x.com/DrBrandonHishttps://www.linkedin.com/in/abraham-morgentaler-md-81628b6/https://x.com/DrMorgentalerhttps://t4leducation.com/https://a.co/d/hZHpFn0 Host: https://www.meredithforreal.com/ https://www.instagram.com/meredithforreal/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal https://www.facebook.com/meredithforrealthecuriousintrovert Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/ 00:00 — Midlife dating déjà vu01:00 — Where have the good ones gone?02:03 — Top complaints while dating03:10 — Picky or self-aware?04:02 — Tiny towns vs. big cities05:00 — Strangers, apps, and mistrust05:58 — Why men send dick pics07:00 — Filtering for “fast yes”08:05 — Who's actually relationship-minded?08:45 — Is app culture the problem?09:20 — Entertainment vs. reciprocity09:58 — Should serious daters ditch apps?10:40 — The slot-machine effect11:35 — Standards vs. pickiness12:15 — Are we avoiding compromise?13:20 — The myth of perfection14:05 — How good men spend time15:00 — Apps aren't on your side16:12 — Ancient brains, modern tools17:00 — Digital dating = amplified disappointment18:00 — Get out of the house19:00 — Pick the rRequest to join my private Facebook Group, MFR Curious Insiders https://www.facebook.com/share/g/1BAt3bpwJC/
Women, Wealth and Entrepreneurship Podcast Season 6, 2025Welcome to Women, Wealth & Entrepreneurship with Ariel Shaw, MBA! We want to increase your bottom line and create generational wealth that lasts way beyond you! It's 2025 and we are in Season 6! Wow! How Exciting! This is the year of Focus and Continued Expansion. Our 2025 Media Participants Include Sylvia Dennis-Wray of Sylvia The Advocate; Mica Johnson of The Mica Johnson State Farm Agency; Shamica Davis of JTS Vacations LLC; LaQuita Brooks of The Motivational Maven.We welcome Dr. John C. Lipman, MD, FSIR. Founder & Medical Director of Atlanta Fibroid Center.Dr. John Lipman is a board-certified Interventional Radiologist and renowned authority in the non-surgical treatment of uterine fibroids. He is also a philanthropist, entrepreneur, and an award-winning public speaker. He received his Masters and Medical degrees from Georgetown University School of Medicine in 1985. He completed a residency in Diagnostic Radiology at Brigham & Women's Hospital, Harvard Medical School, and then did a fellowship in Vascular & Interventional Radiology at Yale-New Haven Hospital, Yale University School of Medicine.
Today's conversation centers on a vital aspect of our human experience. The enhancing richness and benefits of empathy. Meet Helen Riess, M.D., Founder and Chief Medical Officer of Empathetics.com. Dr. Riess is a clinical professor and research psychiatrist at Harvard Medical School who developed empathy education based on neuroscience research. Her groundbreaking book, which is now in paperback, is entitled, “The Empathy Effect: 7 NEUROSCIENCE BASED KEYS for Transforming the Way We LIVE, LOVE, WORK and CONNECT Across Differences.” In a fractured world, learning more about empathy could be just what we need!
Madelaine Weiss is a Harvard-trained Licensed Psychotherapist, Mindset Expert, and Board-Certified Executive, Career, and Life Coach who helps high-achieving professionals master their minds so they can sustain—and truly enjoy—success across every area of life.She is the co-author of The Handbook of Stressful Transitions Across the Lifespan and the author of the acclaimed new release Getting to G.R.E.A.T.: 5-Step Strategy for Work and Life.Continuing her mission to support leaders both at work and at home, Madelaine is launching What's Your Story?, a personal development workbook for children and the adults who care about them. Her expertise in this space is rooted in her past roles as Chair of the School Business Partnership and as a parenting educator for the Massachusetts court system.Madelaine also brings deep organizational experience to her work, having served as a group mental health practice administrative director, a corporate Chief Organizational Development Officer, and an associate director of an educational resource program at Harvard Medical School.As a sought-after corporate trainer, she has designed and delivered programs for organizations including Harvard Medical School, the American Bar Association, Legal Services Corporation, AARP, MedSense, Harvard Law School Association, the International Association of Business Communicators, the National Association of Realtors, the DC Academy of General Dentistry, the Wharton Innovation Summit, and the Bureau of National Affairs.Madelaine's insights have been featured on NBC, Bold TV, and FOX5, and she is a frequent guest expert on leading podcasts, including Major, Lindsey & Africa's Erasing the Stigma. Her writing has appeared in Thrive Global, Authority Magazine's Editors List, UpJourney, and My Perfect Financial Advisor.
Start Your Transformation Now In this episode of the Transform Your Life podcast, I talk about the importance of living your own purpose in life rather than conforming to the expectations and ideals of others. I talk about how we can get stuck in careers, relationships, and situations that don't align with our true desires because we seek the approval of our parents, partners, and society. I ask you to explore whether you are truly living a purposeful, fulfilling life on your own terms or living your life for others. As I ask the last question, I think back to the 1991 movie, The Dead Poet's Society, and I think about the movie character named Neil. He wanted to pursue acting and loved it, but his stern father wanted him to go to Harvard Medical School. Neil hated the idea of medical school and found it soul-crushing, but he agreed. You'll have to watch the movie for the story's conclusion, but it's not uncommon for people to deny their own hopes, wishes, wants, and dreams and instead live their lives to please their parents. Often times cultural and familial pressures guide people down a path that doesn't fulfill them, and they live decades misaligned from their own purpose while trying to please others. So, it's important to ask whether you are living your own purpose or someone else's. Another purpose-robbing action that people often get into is seeking validation from others. This is a surefire way to live an unfulfilled life. For example, a friend of mine was constantly motivated by a desire for his father's approval, and that led him down an obsessive path of constantly trying to prove himself. This behavior disconnects you from your higher self and obscures your true purpose. You can't create an authentic life while dependent on external validation. I have found that the key to living your purpose is surrendering to your destiny and innate talents. This involves getting quiet, listening to your intuition, and taking aligned action. We must focus on the importance of being grateful and on contribution rather than achievement. Here are four key points you may want to keep in mind: Surrender to your innate talents and destiny.Listen to your intuition and take aligned action.Express gratitude and focus on contributing.Achievements will naturally follow purposeful contributions. You must examine whether you are living someone else's purpose or your own. If you are not thrilled by how you spend your days, you are likely conforming to others' expectations. I challenge you to get creative, listen within, and take steps each day to live your own purpose. Listen, apply, and enjoy! Transformational Takeaway When you are living your purpose, you are contributing your talents to activities that light you up, and you will experience true joy and fulfillment. Your key is being brave enough to live life on your own terms. Just do it. Mentioned Resources: EPISODE 280: History, Humanity, and Spiritual Ego. EPISODE 236: Living Life on Your Own Terms Let's Connect:Instagram | Facebook | YouTube | LinkedIn LIKED THE EPISODE?If you're the kind of person who likes to help others, then share this with your friends and family. If you have found value, they will too. Please leave a review on Apple Podcasts so we can reach more people. Listening on Spotify? Please leave a comment below. We would love to hear from you! With gratitude,Jim
From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this inaugural episode, Dr Matulonis welcomed guest Taymaa May, MD, MSc, to discuss advances in gynecologic cancer surgery. Dr May is the director of Ovarian Cancer Surgery in the Division of Surgical Oncology at the Brigham and Women's Hospital in Boston, as well as an associate professor at Harvard Medical School. One of the biggest transformative changes in the field has been the introduction of minimally invasive surgery using laparoscopic and robotic platforms, Dr May emphasized. This allows for precise cancer staging surgery and faster patient recovery without compromising cancer outcomes, she noted. Complementing this has been the innovation of sentinel lymph node mapping, which uses technology, such as an infrared dye, to precisely identify and remove only the necessary lymph nodes. This offers equal staging precision and reduces patient morbidity with lower extremity lymphedema, a common adverse effect associated with older, extensive lymph node dissections, according to Dr May. The experts stressed the importance of consulting a gynecologic oncology surgeon, as national studies indicate that patients assessed and operated on by these specialists achieve the most optimal clinical outcomes. For advanced ovarian cancer, which often requires complex multivisceral resection to achieve optimal tumor removal, Dr May explained that surgical innovations are used to enhance recovery. For example, she noted that fluorescence angiography assesses blood flow in fresh bowel sutures intraoperatively, which helps ensure proper healing and minimizes complications. In cervical cancer, Dr May said that radical trachelectomy offers a safe, fertility-preserving option for young patients with suitable tumors. Furthermore, when determining treatment for patients with advanced ovarian cancer, she emphasized that personalization is key. Ultimately, Drs Matulonis and May reported that integrating surgical innovation into gynecologic cancer treatment protocols ensures optimal recovery, which is critical for patients to start subsequent treatments, like chemotherapy, on time.
For episode 273, we are continuing a new series on the Metta Hour, centered on kids, in honor of Sharon's first children's book, Kind Karl, coming out on December 9th!Co-authored by Jason Gruhl, this illustrated picture book is for 4-8 year-olds and is a new children's adaptation of Sharon's beloved book Lovingkindness. For this podcast series, Sharon speaks with educators, caregivers, and researchers about the ways meditation, mindfulness, and lovingkindness can impact children of all ages and the family systems that support them. For the second episode of the series, Sharon speaks with Dr. Christopher Willard.Chris is a clinical psychologist at Harvard Medical School and author of numerous publications for children and adults. An internationally sought-after speaker and mindfulness educator, his books include Growing Up Mindful, Raising Resilience, and Alphabreaths.In this conversation, Sharon and Chris speak about:The benefits of mindfulness in family systemsChris's personal journey with mindfulnessHow mindfulness can be accessible for kids Emotional growth and connection at any age Simple at-home practices Modeling calm compassion How kids can emotionally regulate The benefits of meditation in schools Challenges of technology in family lifeHow self-compassion prevents burnoutNurturing empathy, presence and resilience The goal of presence, not perfectionThe episode closes with Chris leading guided practice. You can learn more about Chris's work on his website, right here.To learn more about Sharon's forthcoming children's book, Kind Karl, and pre-order a copy with a special pre-order gift, you can visit Sharon's website, right here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Welcome to the O2X limited series Optimizing Parenthood - A Guide to Leading the Next Generation.Over this 5 episode limited series we will explore the science, strategies, and practical wisdom behind raising healthy, confident, and resilient young adults. Hosted by O2X Vice President of Government Brendan Stickles, this podcast brings together leading experts in sleep science, nutrition, fitness, psychology, and personal development to help parents navigate the complexities of modern parenting.Episode #2 features O2X Sleep & Fatigue Management Specialist Jaime Lee Tartar. Dr. Tartar is a Professor of Neuroscience at Nova Southeastern University (NSU). She serves as the neuroscience program director and research director for the NSU College of Psychology. She received her Bachelor of Science degree in Psychology from NSU and a Master of Arts degree in Psychology from Florida Atlantic University where she used EEG measure to detect subclinical neurological impairments. She earned her Ph.D. in the Behavioral Neuroscience program at the University of Florida where the focus of her research involved discovering long-term changes that occur in neurobiological pathways involved in stress responses and developing animal models of stress. During graduate school Dr. Tartar also served for 6 years in the U.S. Army Reserves. Dr. Tartar completed Postdoctoral Training at Harvard Medical School where she studied neurological consequences of sleep perturbations using in vitro electrophysiological recording techniques. She also received training in Sleep Medicine at Harvard Medical School. In her professional career Dr. Tartar was awarded an Honorary Doctorate from NSU based on her work and contributions to NSU and the scientific community. She was also the NSU Professor of the year at NSU in 2018 and received the NSU Excellence in Teaching Award in 2009. Dr. Tartar has received multiple funding grants through the Department of Education and has received research funding from the Department of Defense. She has published over 55 original research articles and has written several book chapters. Based on her expertise, she consults for multiple prestigious organizations and served on the scientific advisory board for the National Academy of Sports Medicine and regularly serves as a peer review panelist for NASA. Dr. Tartar is also a scientific advisor for Enchanted Wave, LLC where she oversees their research in using single channel EEG. She is the co-founder and President of The Society for NeuroSports — an academic organization for the field of Sports Neuroscience. Dr. Tartar's current research is focused on stress, sleep, and athletic performance in humans.Be sure to tune into the following episodes over the following weeks...Episode 1: Dr. Katy Turner on building confidence and resilience within young adults Episode 2: Dr. Jaime Tartar on optimizing sleep schedules for the whole family Episode 3: Josh Lamont on creating fitness habits in our youthEpisode 4: Dr. Nick Barringer on developing sustainable and healthy eating habitsEpisode 5: Adam La Reau on introducing goal setting and habit building to young adultsBuilding Homes for Heroes:https://www.buildinghomesforheroes.org/Download the O2X Tactical Performance App:app.o2x.comLet us know what you think:Website - http://o2x.comIG - https://instagram.com/o2xhumanperformance?igshid=1kicimx55xt4f
In the latest episode, The Fanbase Weekly co-hosts welcome special guests Matthew Noe (Lead Collection & Knowledge Management Librarian, Harvard Medical School) and Tim Smyth (Educator / Reading Specialist / Eisner-nominated author - Teaching with Comics & Graphic Novels) to discuss the latest geek news stories of the week, including AI's attacks on libraries, education, and knowledge, whether Ben Solo should return to the Star Wars films, and James Cameron's connection to Predator: Badlands.
Listen to JCO's Art of Oncology article, "The Man at the Bow" by Dr. Alexis Drutchas, who is a palliative care physician at Dana Farber Cancer Institute. The article is followed by an interview with Drutchas and host Dr. Mikkael Sekeres. Dr. Drutchas shares the deep connection she had with a patient, a former barge captain, who often sailed the same route that her family's shipping container did when they moved overseas many times while she was growing up. She reflects on the nature of loss and dignity, and how oncologists might hold patients' humanity with more tenderness and care, especially at the end of life. TRANSCRIPT Narrator: The Man at the Bow, by Alexis Drutchas, MD It was the kind of day that almost seemed made up—a clear, cerulean sky with sunlight bouncing off the gold dome of the State House. The contrast between this view and the drab hospital walls as I walked into my patient's room was jarring. My patient, whom I will call Suresh, sat in a recliner by the window. His lymphoma had relapsed, and palliative care was consulted to help with symptom management. The first thing I remember is that despite the havoc cancer had wreaked—sunken temples and a hospital gown slipping off his chest—Suresh had a warm, peaceful quality about him. Our conversation began with a discussion about his pain. Suresh told me how his bones ached and how his fatigue left him feeling hollow—a fraction of his former self. The way this drastic change in his physicality affected his sense of identity was palpable. There was loss, even if it was unspoken. After establishing a plan to help with his symptoms, I pivoted and asked Suresh how he used to spend his days. His face immediately lit up. He had been a barge captain—a dangerous and thrilling profession that took him across international waters to transport goods. Suresh's eyes glistened as he described his joy at sea. I was completely enraptured. He shared stories about mornings when he stood alone on the bow, feeling the salted breeze as the barge moved through Atlantic waves. He spoke of calm nights on the deck, looking at the stars through stunning darkness. He traveled all over the globe and witnessed Earth's topography from a perspective most of us will never see. The freedom Suresh exuded was profound. He loved these voyages so much that one summer, despite the hazards, he brought his wife and son to experience the journey with him. Having spent many years of my childhood living in Japan and Hong Kong, my family's entire home—every bed, sheet, towel, and kitchen utensil—was packed up and crossed the Atlantic on cargo ships four times. Maybe Suresh had captained one, I thought. Every winter, we hosted US Navy sailors docked in Hong Kong for the holidays. I have such fond memories of everyone going around the table and sharing stories of their adventures—who saw or ate what and where. I loved those times: the wild abandon of travel, the freedom of being somewhere new, and the way identity can shift and expand as experiences grow. When Suresh shared stories of the ocean, I was back there too, holding the multitude of my identity alongside him. I asked Suresh to tell me more about his voyages: what was it like to be out in severe weather, to ride over enormous swells? Did he ever get seasick, and did his crew always get along? But Suresh did not want to swim into these perilous stories with me. Although he worked a difficult and physically taxing job, this is not what he wanted to focus on. Instead, he always came back to the beauty and vitality he felt at sea—what it was like to stare out at the vastness of the open ocean. He often closed his eyes and motioned with his hands as he spoke as if he was not confined to these hospital walls. Instead, he was swaying on the water feeling the lightness of physical freedom, and the way a body can move with such ease that it is barely perceptible, like water flowing over sand. The resonances of Suresh's stories contained both the power and challenges laden in this work. Although I sat at his bedside, healthy, my body too contained memories of freedom that in all likelihood will one day dissipate with age or illness. The question of how I will be seen, compared to how I hoped to be seen, lingered in my mind. Years ago, before going to medical school, I moved to Vail, Colorado. I worked four different jobs just to make ends meet, but making it work meant that on my days off, I was only a chairlift ride away from Vail's backcountry. I have a picture of this vigor in my mind—my snowboard carving into fresh powder, the utter silence of the wilderness at that altitude, and the way it felt to graze the powdery snow against my glove. My face was windburned, and my body was sore, but my heart had never felt so buoyant. While talking with Suresh, I could so vividly picture him as the robust man he once was, standing tall on the bow of his ship. I could feel the freedom and joy he described—it echoed in my own body. In that moment, the full weight of what Suresh had lost hit me as forcefully as a cresting wave—not just the physical decline, but the profound shift in his identity. What is more, we all live, myself included, so precariously at this threshold. In this work, it is impossible not to wonder: what will it be like when it is me? Will I be seen as someone who has lived a full life, who explored and adventured, or will my personhood be whittled down to my illness? How can I hold these questions and not be swallowed by them? "I know who you are now is not the person you've been," I said to Suresh. With that, he reached out for my hand and started to cry. We looked at each other with a new understanding. I saw Suresh—not just as a frail patient but as someone who lived a full life. As someone strong enough to cross the Atlantic for decades. In that moment, I was reminded of the Polish poet, Wislawa Szymborska's words, "As far as you've come, can't be undone." This, I believe, is what it means to honor the dignity of our patients, to reflect back the person they are despite or alongside their illness…all of their parts that can't be undone. Sometimes, this occurs because we see our own personhood reflected in theirs and theirs in ours. Sometimes, to protect ourselves, we shield ourselves from this echo. Other times, this resonance becomes the most beautiful and meaningful part of our work. It has been years now since I took care of Suresh. When the weather is nice, my wife and I like to take our young son to the harbor in South Boston to watch the planes take off and the barges leave the shore, loaded with colorful metal containers. We usually pack a picnic and sit in the trunk as enormous planes fly overhead and tugboats work to bring large ships out to the open water. Once, as a container ship was leaving the port, we waved so furiously at those working on board that they all started to wave back, and the captain honked the ships booming horn. Every single time we are there, I think of Suresh, and I picture him sailing out on thewaves—as free as he will ever be. Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a treat we have today. We're joined by Dr. Alexis Drutchas, a Palliative Care Physician and the Director of the Core Communication Program at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School to discuss her article, "The Man at the Bow." Alexis, thank you so much for contributing to Journal of Clinical Oncology and for joining us to discuss your article. Dr. Alexis Drutchas: Thank you. I'm thrilled and excited to be here. Mikkael Sekeres: I wonder if we can start by asking you about yourself. Where are you from, and can you walk us a bit through your career? Dr. Alexis Drutchas: The easiest way to say it would be that I'm from the Detroit area. My dad worked in automotive car parts and so we moved around a lot when I was growing up. I was born in Michigan, then we moved to Japan, then back to Michigan, then to Hong Kong, then back to Michigan. Then I spent my undergrad years in Wisconsin and moved out to Colorado to teach snowboarding before medical school, and then ended up back in Michigan for that, and then on the east coast at Brown for my family medicine training, and then in Boston for work and training. So, I definitely have a more global experience in my background, but also very Midwestern at heart as well. In terms of my professional career trajectory, I trained in family medicine because I really loved taking care of the whole person. I love taking care of kids and adults, and I loved OB, and at the time I felt like it was impossible to choose which one I wanted to pursue the most, and so family medicine was a great fit. And at the core of that, there's just so much advocacy and social justice work, especially in the community health centers where many family medicine residents train. During that time, I got very interested in LGBTQ healthcare and founded the Rhode Island Trans Health Conference, which led me to work as a PCP at Fenway Health in Boston after that. And so I worked there for many years. And then through a course of being a hospitalist at BI during that work, I worked with many patients with serious illness, making decisions about discontinuing dialysis, about pursuing hospice care in the setting of ILD. I also had a significant amount of family illness and started to recognize this underlying interest I had always had in palliative care, but I think was a bit scared to pursue. But those really kind of tipped me over to say I really wanted to access a different level of communication skills and be able to really go into depth with patients in a way I just didn't feel like I had the language for. And so I applied to the Harvard Palliative Care Fellowship and luckily and with so much gratitude got in years ago, and so trained in palliative care and stayed at MGH after that. So my Dana-Farber position is newer for me and I'm very excited about it. Mikkael Sekeres: Sounds like you've had an amazing career already and you're just getting started on it. I grew up in tiny little Rhode Island and, you know, we would joke you have to pack an overnight bag if you travel more than 45 minutes. So, our boundaries were much tighter than yours. What was it like growing up where you're going from the Midwest to Asia, back to the Midwest, you wind up settling on the east coast? You must have an incredible worldly view on how people live and how they view their health. Dr. Alexis Drutchas: I think you just named much of the sides of it. I think I realize now, in looking back, that in many ways it was living two lives, because at the time it was rare from where we lived in the Detroit area in terms of the other kids around us to move overseas. And so it really did feel like that part of me and my family that during the summers we would have home leave tickets and my parents would often turn them in to just travel since we didn't really have a home base to come back to. And so it did give me an incredible global perspective and a sense of all the ways in which people develop community, access healthcare, and live. And then coming back to the Midwest, not to say that it's not cosmopolitan or diverse in its own way, but it was very different, especially in the 80s and 90s to come back to the Midwest. So it did feel like I carried these two lenses in the world, and it's been incredibly meaningful over time to meet other friends and adults and patients who have lived these other lives as well. I think for me those are some of my most connecting friendships and experiences with patients for people who have had a similar experience in living with sort of a duality in their everyday lives with that. Mikkael Sekeres: You know, you write about the main character of your essay, Suresh, who's a barge captain, and you mention in the essay that your family crossed the Atlantic on cargo ships four times when you were growing up. What was that experience like? How much of it do you remember? Dr. Alexis Drutchas: Our house, like our things, crossed the Atlantic four times on barge ships such as his. We didn't, I mean we crossed on airplanes. Mikkael Sekeres: Oh, okay, okay. Dr. Alexis Drutchas: We flew over many times, but every single thing we owned got packed up into containers on large trucks in our house and were brought over to ports to be sent over. So, I'm not sure how they do it now, but at the time that's sort of how we moved, and we would often go live in a hotel or a furnished apartment for the month's wait of all of our house to get there, which felt also like a surreal experience in that, you know, you're in a totally different country and then have these creature comforts of your bedroom back in Metro Detroit. And I remember thinking a lot about who was crossing over with all of that stuff and where was it going, and who else was moving, and that was pretty incredible. And when I met Suresh, just thinking about the fact that at some point our home could have been on his ship was a really fun connection in my mind to make, just given where he always traveled in his work. Mikkael Sekeres: It's really neat. I remember when we moved from the east coast also to the Midwest, I was in Cleveland for 18 years. The very first thing we did was mark which of the boxes had the kids' toys in it, because that of course was the first one we let them close it up and then we let them open it as soon as we arrived. Did your family do something like that as well so that you can, you know, immediately feel an attachment to your stuff when they arrived? Dr. Alexis Drutchas: Yeah, I remember what felt most important to our mom was our bedrooms. I don't remember the toys. I remember sort of our comforters and our pillowcases and things like that, yeah, being opened and it feeling really settling to think, "Okay, you know, we're in a completely different place and country away from most everything we know, but our bedroom is the same." That always felt like a really important point that she made to make home feel like home again in a new place. Mikkael Sekeres: Yeah, yeah. One of the sentences you wrote in your essay really caught my eye. You wrote about when you were younger and say, "I loved those times, the wild abandon of travel, the freedom of being somewhere new, the way identity can shift and expand as experiences grow." It's a lovely sentiment. Do you think those are emotions that we experience only as children, or can they continue through adulthood? And if they can, how do we make that happen, that sense of excitement and experience? Dr. Alexis Drutchas: I think that's such a good question and one I honestly think about a lot. I think that we can access those all the time. There's something about the newness of travel and moving, you know, I have a 3-year-old right now, and so I think many parents would connect to that sense that there is wonderment around being with someone experiencing something for the first time. Even watching my son, Oliver, see a plane take off for the first time felt joyous in a completely new way, that even makes me smile a lot now. But I think what is such a great connection here is when something is new, our eyes are so open to it. You know, we're constantly witnessing and observing and are excited about that. And I think the connection that I've realized is important for me in my work and also in just life in general to hold on to that wonderment is that idea of sort of witnessing or having a writer's eye, many would call it, in that you're keeping your eye open for the small beautiful things. Often with travel, you might be eating ramen. It might not be the first time you're eating it, but you're eating it for the first time in Tokyo, and it's the first time you've had this particular ingredient on it, and then you remember that. But there's something that we're attuned to in those moments, like the difference or the taste, that makes it special and we hold on to it. And I think about that a lot as a writer, but also in patient care and having my son with my wife, it's what are the special small moments to hold on to and allowing them to be new and beautiful, even if they're not as large as moving across the country or flying to Rome or whichever. I think there are ways that that excitement can still be alive if we attune ourselves to some of the more beautiful small moments around us. Mikkael Sekeres: And how do we do that as doctors? We're trained to go into a room and there's almost a formula for how we approach patients. But how do you open your mind in that way to that sense of wonderment and discovery with the person you're sitting across from, and it doesn't necessarily have to be medical? One of the true treats of what we do is we get to meet people from all backgrounds and all walks of life, and we have the opportunity to explore their lives as part of our interaction. Dr. Alexis Drutchas: Yeah, I think that is such a great question. And I would love to hear your thoughts on this too. I think for me in that sentence that you mentioned, sitting at that table with sort of people in the Navy from all over the world, I was that person to them in the room, too. There was some identity there that I brought to the table that was different than just being a kid in school or something like that. To answer your question, I wonder if so much of the challenge is actually allowing ourselves to bring ourselves into the room, because so much of the formula is, you know, we have these white coats on, we have learners, we want to do it right, we want to give excellent care. There's there's so many sort of guards I think that we put up to make sure that we're asking the right questions, we don't want to miss anything, we don't want to say the wrong thing, and all of that is true. And at the same time, I find that when I actually allow myself into the room, that is when it is the most special. And that doesn't mean that there's complete countertransference or it's so permeable that it's not in service of the patient. It just means that I think when we allow bits of our own selves to come in, it really does allow for new connections to form, and then we are able to learn about our patients more, too. With every patient, I think often we're called in for goals of care or symptom management, and of course I prioritize that, but when I can, I usually just try to ask a more open-ended question, like, "Tell me about life before you came to the hospital or before you were diagnosed. What do you love to do? What did you do for work?" Or if it's someone's family member who is ill, I'll ask the kids or family in the room, "Like, what kind of mom was she? You know, what special memory you had?" Just, I get really curious when there's time to really understand the person. And I know that that's not at all new language. Of course, we're always trying to understand the person, but I just often think understanding them is couched within their illness. And I'm often very curious about how we can just get to know them as people, and how humanizing ourselves to them helps humanize them to us, and that back and forth I think is like really lovely and wonderful and allows things to come up that were totally unexpected, and those are usually the special moments that you come home with and want to tell your family about or want to process and think about. What about you? How do you think about that question? Mikkael Sekeres: Well, it's interesting you ask. I like to do projects around the house. I hate to say this out loud because of course one day I'll do something terrible and everyone will remember this podcast, but I fancy myself an amateur electrician and plumber and carpenter and do these sorts of projects. So I go into interactions with patients wanting to learn about their lives and how they live their lives to see what I can pick up on as well, how I can take something out of that interaction and actually use it practically. My father-in-law has this phrase he always says to me when a worker comes to your house, he goes, he says to me, "Remember to steal with your eyes." Right? Watch what they do, learn how they fix something so you can fix it yourself and you don't have to call them next time. So, for me it's kind of fun to hear how people have lived their lives both within their professions, and when I practiced medicine in Cleveland, there were a lot of farmers and factory workers I saw. So I learned a lot about how things are made. But also about how they interact with their families, and I've learned a lot from people I've seen who were just terrific dads and terrific moms or siblings or spouses. And I've tried to take those nuggets away from those interactions. But I think you can only do it if you open yourself up and also allow yourself to see that person's humanity. And I wonder if I can quote you to you again from your essay. There's another part that I just loved, and it's about how you write about how a person's identity changes when they become a patient. You write, "And in that moment the full weight of what he had lost hit me as forcefully as a cresting wave. Not just the physical decline, but the profound shift in identity. What is more, we all live, me included, so precariously at this threshold. In this work, it's impossible not to wonder, what will it be like when it's me? Will I be seen as someone who's lived many lives, or whittled down only to someone who's sick?" Can you talk a little bit more about that? Have you been a patient whose identity has changed without asking you to reveal too much? Or what about your identity as a doctor? Is that something we have to undo a little bit when we walk in the room with the stethoscope or wearing a white coat? Dr. Alexis Drutchas: That was really powerful to hear you read that back to me. So, thank you. Yeah, I think my answer here can't be separated from the illness I faced with my family. And I think this unanimously filters into the way in which I see every patient because I really do think about the patient's dignity and the way medicine generally, not always, really does strip them of that and makes them the patient. Even the way we write about "the patient said this," "the patient said that," "the patient refused." So I generally very much try to have a one-liner like, "Suresh is a X-year-old man who's a barge captain from X, Y, and Z and is a loving father with a," you know, "period. He comes to the hospital with X, Y, and Z." So I always try to do that and humanize patients. I always try to write their name rather than just "patient." I can't separate that out from my experience with my family. My sister six years ago now went into sudden heart failure after having a spontaneous coronary artery dissection, and so immediately within minutes she was in the cath lab at 35 years old, coding three times and came out sort of with an Impella and intubated, and very much, you know, all of a sudden went from my sister who had just been traveling in Mexico to a patient in the CCU. And I remember desperately wanting her team to see who she was, like see the person that we loved, that was fighting for her life, see how much her life meant to us. And that's not to say that they weren't giving her great care, but there was something so important to me in wanting them to see how much we wanted her to live, you know, and who she was. It felt like there's some important core to me there. We brought pictures in, we talked about what she was living for. It felt really important. And I can't separate that out from the way in which I see patients now or I feel in my own way in a certain way what it is to lose yourself, to lose the ability to be a Captain of the ship, to lose the ability to do electric work around the house. So much of our identity is wrapped up in our professions and our craft. And I think for me that has really become forefront in the work of palliative care and in and in the teaching I do and in the writing I do is how to really bring them forefront and not feel like in doing that we're losing our ability to remain objective or solid in our own professional identities as clinicians and physicians. Mikkael Sekeres: Well, I think that's a beautiful place to end here. I can only imagine what an outstanding physician and caregiver you are also based on your writing and how you speak about it. You just genuinely come across as caring about your patients and your family and the people you have interactions with and getting to know them as people. It has been again such a treat to have Dr. Alexis Drutchas here. She is Director of the Core Communication Program at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School to discuss her article, "The Man at the Bow." Alexis, thank you so much for joining us. Dr. Alexis Drutchas: Thank you. This has been a real joy. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague, or leave us a review. Your feedback and support helps us continue to save these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at ASCO.org/podcasts. Until next time, this has been Mikkael Sekeres for the ASCO podcast Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio: Dr. Alexis Drutchas is a palliative care physician at Dana Farber Cancer Institute.
LAST CHANCE – Expires November 21! Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach. Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
What if AI could help solve medicine's biggest blind spots?Harvard Medical School researcher Dr. Charlotte Blease reveals why doctors can only keep up with 2% of new medical research and how artificial intelligence could transform healthcare for both patients and providers. Drawing from her new book Dr Bot: Why Doctors Can Fail and How AI Could Save Lives, she shares fascinating insights about the future of medical care.Part of the Future of Medicine series exploring innovations reshaping healthcare as we know it.You can find Charlotte at: Dr Bot Substack | Website | Episode TranscriptIf you LOVED this episode, don't miss a single conversation in our Future of Medicine series, airing every Monday through December. Follow Good Life Project wherever you listen to podcasts to catch them all.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount CodesWatch Jonathan's new TEDxBoulder Talk on YouTube now: https://www.youtube.com/watch?v=2zUAM-euiVI Hosted on Acast. See acast.com/privacy for more information.
I am thrilled to have Dr. Olivera Bogunovic and Holly Hardman with me on the show today. Dr. Bogunovic is an assistant professor of psychiatry at Harvard Medical School and the medical director of the alcohol, drug, and addiction outpatient program at McLean Hospital. and Holly directed the documentary As Prescribed. In today's discussion, we dive into the ongoing benzodiazepine crisis in the United States, with over 92 million prescriptions written each year for medications like Ativan, Valium, Xanax, and Klonopin. We discuss the origin of those drugs in the 1970s as treatments for anxiety and how they lead to tremendous physical dependency. Holly shares her experience with the neurological effects she suffered after long-term use of Klonopin, and we examine challenges in psychiatric care, the need for informed consent, and the impact of social media. We also cover the role of lifestyle, the need for psychotherapy and psychosocial support, and the significance of hope. This conversation is truly invaluable! Given how frequently benzodiazepines get prescribed, everyone must understand their associated risks and considerations. IN THIS EPISODE YOU WILL LEARN: How prescribing practices have evolved over the last two decades The significant consequences older adults face when they suddenly stop using benzodiazepines Holly shares how doctors misinformed her when she began taking Klonopin. Holly describes the benzodiazepine-induced symptoms and cognitive issues she experienced Why people must get informed about the long-term effects of benzodiazepines when consenting to take them How benzodiazepines work in the body and impact the brain Why benzodiazepines are ineffective when used long-term for insomnia The challenges certain people face when accessing psychiatric care What is BIND, and what are its symptoms? The significance of diet and holistic approaches for managing mental health, and why community support is essential in the recovery process Why As Prescribed is an educational documentary for everyone Connect with Cynthia Thurlow Follow on X Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Olivera Bogunovic The McLean Hospital The documentary, As Prescribed, is available in the United States and Canada on Prime Video, Apple, Kanopy, Tubi, and Google.
It's simple to calm your nervous system in minutes using a meditation technique taught by Dr. Juna. In this episode of the MindBodySpace Podcast, Dr. Juna, a double board-certified radiologist and lifestyle medicine physician, guides you through a relaxation response method inspired by Dr. Herbert Benson's work at Harvard Medical School on meditation and blood pressure. You'll learn how to interrupt everyday thoughts, reduce stress, and activate your parasympathetic nervous system, resulting in a lower heart rate and relaxed muscle tension and a whole host of other benefits. For more resources, visit mindbodyspace.com00:00 Introduction to Relaxation Response00:33 Understanding Stress and Relaxation Response01:41 Guided Relaxation Exercise09:17 Concluding Thoughts and Resources
A Cleveland TV news reporter who once told other people’s stories becomes the subject of her own. Two Massachusetts men are charged after allegedly setting off a commercial firework inside Harvard Medical School. Drew Nelson reports.See omnystudio.com/listener for privacy information.
We start with the final hours of voting in key races across the country. Anxiety around travel spikes as the government barrels towards its longest shutdown. Authorities made arrests in connection with a blast at Harvard Medical School. There's a major recall impacting some Jeep SUVs worldwide. Plus, a new hurdle in the fight against climate change. Learn more about your ad choices. Visit podcastchoices.com/adchoices
This popular episode replay features Dr. David H. Rosmarin, an associate professor at Harvard Medical School, a program director at McLean Hospital, and founder of Center for Anxiety, which services over 1,000 patients/year in multiple states. He is an international expert on spirituality and mental health, whose work has been featured in Scientific American, the Boston Globe, the Wall Street Journal, and the New York Times. Through his work as a clinical psychologist, scientist, educator and author, Dr. Rosmarin has helped thousands of patients and organizations to live happier and more productive lives. His most recent book is Thriving with Anxiety: 9 Tools to Make Your Anxiety Work for You Key Topics: - The current anxiety epidemic and what is causing it - Anxiety as a stepping stone to connection - How fear is a natural alert - How anxiety makes us connect to others better - The difference between stress and anxiety - How anxiety enhances spirituality - Hope for the person who's drowning in anxiety - The least known contributor to anxiety Learn more about Dr. Rosmarin and get his book at drrosmarin.com and centerforanxiety.org. Join Erin's monthly mailing list to get health tips and fresh meal plans and recipes every month: https://mailchi.mp/adde1b3a4af3/monthlysparksignup Order Erin's new book, Live Beyond Your Label, at erinbkerry.com/upcomingbook/ Buy Erin's recipe book, co-written by pediatrician Dr. Alina Olteanu here: https://a.co/d/ateoVxx
Milk has long been sold as the key to strong bones, but research challenges that claim: many people don't tolerate dairy, calcium needs are lower than advertised, and higher milk intake doesn't necessarily prevent fractures. Politics and industry marketing helped set “three glasses a day,” even though healthy bones depend more on overall diet and lifestyle—things like vitamin D, movement, and avoiding soda, excess sugar, and stress that drive calcium loss. Dairy may be helpful for some diets, but it can also trigger bloating, acne, congestion, or digestive issues. The good news is that strong bones and good nutrition are still very doable without cow's milk—think leafy greens, sardines, almonds, chia, and sunshine for vitamin D. In this episode, I discuss, along with Dr. David Ludwig and Dr. Elizabeth Boham why bone health depends more on diet, lifestyle, and nutrient balance than on dairy. David S. Ludwig, MD, PhD, is an endocrinologist and researcher at Boston Children's Hospital, Professor of Pediatrics at Harvard Medical School, and Professor of Nutrition at the Harvard T.H. Chan School of Public Health. He co-directs the New Balance Foundation Obesity Prevention Center and founded the Optimal Weight for Life (OWL) program, one of the nation's largest clinics for children with obesity. For over 25 years, Dr. Ludwig has studied how diet composition affects metabolism, body weight, and chronic disease risk, focusing on low glycemic index, low-carbohydrate, and ketogenic diets. Called an “obesity warrior” by Time Magazine, he has championed policy changes to improve the food environment. A Principal Investigator on numerous NIH and philanthropic grants, Dr. Ludwig has published over 200 scientific articles and three books for the public, including the #1 New York Times bestseller Always, Hungry? Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:Why Most Everything We Were Told About Dairy Is Wrong Is It Okay To Eat Cheese And What Types Of Dairy Should You Avoid? Is Lactose Intolerance Causing Your Gut Issues?
National security expert Juliette Kayyem on the investigation into an explosion at a Harvard Medical School building over the weekend, and President Trump's continued attacks on Venezuelan boats, even as the UN cites human rights violations. Plus, why he's threatening U.S. military action in Nigeria.Carol Rose of the ACLU of Massachusetts discusses the ACLU-led class action suit on behalf of detained immigrants who have been denied bond hearings. Plus, whether the U.S. supreme court will hand Trump yet another major victory on tariffs. Michael Curry of the Mass League of Community Health Centers on the government shutdown, healthcare costs and remembering his friend, former Newton mayor Setti Warren.David Shapiro of the YMCA of Greater Boston on how the Y is meeting Boston's food needs during the shutdown. Alexander Smalls is an award-winning opera singer turned James Beard Award-winning cookbook author and chef. He joins us ahead of an event at Suffolk University.
John Edward Mack (October 4, 1929 – September 27, 2004) was an American psychiatrist, writer, and professor of psychiatry. He served as the head of the department of psychiatry at Harvard Medical School from 1977 to 2004. In 1977, Mack won the Pulitzer Prize for his book A Prince of Our Disorder on T. E. Lawrence.Mack's clinical expertise was in child psychology, adolescent psychology, and the psychology of religion. He was also known as a leading researcher on the psychology of teenage suicide and drug addiction, and he later became a researcher in the psychology of alien abduction experiences.Help us buy a camera:https://ko-fi.com/monsterfuzzSupport the pod:www.patreon.com/monsterfuzz Check out our merch:https://monster-fuzz.creator-spring.com Become a supporter of this podcast: https://www.spreaker.com/podcast/monster-fuzz--4349429/support.
Still no end in sight for ending the government shutdown. Dodgers win 2025 MLB World Series. Thwarted terrorist attack: Michigan attorneys say there was no attack planned despite FBI claims. Explosion at Harvard Medical School appears to have been intentional, authorities say. Mid-term elections tomorrow. China will make ‘substantial' purchases of U.S. soybeans and should avoid 100% tariff. Trump says there 'could be' US troops on the ground in Nigeria, or air strikes. Affordability and child care. The dangers of AI ChatBots. The problems with supermarket self-checkouts. Traffic worsening as return-to-the office rules take effect.
In this Huberman Lab Essentials episode, my guest is Dr. David Sinclair, PhD, a professor of genetics at Harvard Medical School and a leading expert on the biology of aging. We discuss the cellular and molecular mechanisms of aging—and how specific behaviors, such as fasting, regular exercise and NAD⁺-boosting compounds like NMN, can activate the body's natural longevity pathways. This discussion highlights how lifestyle choices profoundly influence the aging process and may even slow or reverse key aspects of biological aging. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman David: https://davidprotein.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps (0:00) David Sinclair (0:20) Longevity, Anti-Aging, Aging as a Disease (2:27) Causes of Aging; Epigenome & Genes (4:53) CD & Scratches Analogy, DNA, Silencing & Expressing Genes (6:44) Physical Appearance & Aging (7:36) Sponsor: David (8:54) Childhood Development & Aging, Horvath Clock, Accelerate Aging (11:30) Rates of Puberty & Aging, Growth Hormone (12:37) Body Size & Longevity; Epigenetics (13:07) Fasting, Calorie Restriction & Longevity, Sirtuins, Insulin & Glucose (16:31) Tool: Skip a Meal (17:07) Longer Fasts & Autophagy, “Deep Cleanse” (18:07) Sponsor: AGZ by AG1 (19:36) Fasting, Fluids, Electrolytes (20:16) Sirtuins, Glucose, mTOR & Fasting; Leucine, Tool: Pulsing Behaviors (24:24) Breaking a Fast, Tools: Do Your Best; Transitions (27:00) Sirtuins, NAD, NMN Supplementation (29:04) Sponsor: Eight Sleep (31:10) Iron & Senescent Cells; Personalize Medicine (32:40) Tool: Blood Markers, CRP (34:50) Tool: Aerobic & Resistance Exercise (35:55) Estrogen, Fasting & Fertility; Aging & Rejuvenation (38:20) Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices
Most people don't realize that what happens in the mouth can ripple through the whole body. The balance of the oral microbiome—the community of bacteria living in our mouths—can either protect us or trigger widespread inflammation that affects the heart, joints, and brain. Hidden dental infections or mercury fillings can quietly drive fatigue, autoimmune issues, or dementia—and fixing the mouth often helps the rest of the body heal, too. The good news is that with simple steps like eating whole foods (often removing gluten), cleaning the mouth well, and breathing through the nose, we can protect both our smile and our overall health. When we care for the mouth as part of the body, lasting wellness becomes possible from the inside out. In this episode, Dr. Todd LePine, Dr. Elizabeth Boham, James Nestor, and I talk about how a healthy mouth microbiome is a key to whole-body wellness. Dr. Todd LePine graduated from Dartmouth Medical School and is Board Certified in Internal Medicine, specializing in Integrative Functional Medicine. He is an Institute for Functional Medicine Certified Practitioner. Prior to joining The UltraWellness Center, he worked as a physician at Canyon Ranch in Lenox, MA, for 10 years. Dr. LePine's focus at The UltraWellness Center is to help his patients achieve optimal health and vitality by restoring the natural balance to both the mind and the body. His areas of interest include optimal aging, bio-detoxification, functional gastrointestinal health, systemic inflammation, autoimmune disorders, and the neurobiology of mood and cognitive disorders. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. James Nestor is an author and journalist who has written for Scientific American, Outside, The New York Times, and more. His book, Breath: The New Science of a Lost Art, was an instant New York Times and London Sunday Times bestseller. Breath explores how the human species has lost the ability to breathe properly—and how to get it back. Breath spent 18 weeks on the New York Times bestseller list in the first year of release, and will be translated into more than 30 languages. Breath was awarded the Best General Nonfiction Book of 2020 by the American Society of Journalists and Authors, and was nominated for Best Science Book of 2021 by the Royal Society. Nestor has spoken at Stanford Medical School, Yale School of Medicine, Harvard Medical School, The United Nations, Global Classroom, and appeared on more than 60 radio and television shows, including Fresh Air with Terry Gross, the Joe Rogan Show, and more. He lives and breathes in San Francisco. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:The Functional Medicine Approach To Oral Health Getting Rid of Cold Sores and Canker Sores The Power Of Breath As Medicine
© 2020-2025 Ivy Podcast Discovery LLC
